Pacira Pharma (PCRX) Guides Q4, FY14 Revs Slightly Ahead of Views

Pacira Pharma (NASDAQ: PCRX) provided its unaudited EXPAREL and total revenue estimates for the fourth quarter and full-year 2014.

“We are pleased with the continued success of EXPAREL in the fourth quarter, growth over the previous quarter and growth for the year, which we expect to provide the basis of a strong 2015,” said Dave Stack, president, chief executive officer and chairman of Pacira. “We believe EXPAREL is a significant brand based on our current infiltration indication, as well as future opportunities that may further provide much needed non-opioid treatment options for pain in order to better address the opioid abuse epidemic in the United States.”

EXPAREL Revenue

• Fourth Quarter 2014: Pacira expects $59.0 million in net revenue for EXPAREL in the fourth quarter of 2014, which represents an increase of:
  • 93 percent over $30.5 million in the fourth quarter of 2013.
  • 18 percent sequentially over $50.2 million in the third quarter of 2014.
• Full-Year 2014: Pacira also expects $188.5 million in net revenue for EXPAREL in 2014, a 147 percent increase over $76.2 million in 2013.

Total Revenue

• Fourth Quarter 2014: Pacira expects total revenues of $61.8 million in the fourth quarter of 2014, which represents an increase of:
  • 84 percent over $33.6 million in the fourth quarter of 2013.
  • 19 percent sequentially over $52.0 million in the third quarter of 2014.
• Full-Year 2014: Pacira also expects total revenues of $197.7 million in 2014, a 131 percent increase over $85.6 million in 2013.

*** The consensus is at Q4 revs of $61.5 million and FY14 revs of $197.3 million.

Pacira will provide final financial results and additional information on its financial performance in conjunction with the fourth quarter and year-end 2014 earnings press release and conference call anticipated in late February.

You May Also Be Interested In

• Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
• First BanCorp (FBP) PT Raised to $21 at Keefe, Bruyette & Woods
• Deutsche Bank (DB) Tops Q1 EPS by 1c